Screening for Alzheimer’s Disease: Some Progress
February 23rd, 2011 | 1 Comment | Source: CNN, JAMA, NY TimesIn developed nations, human life expectancy has increased steadily for over a century. One of the few negative consequences of this trend has been a marked increase in the prevalence of Alzheimer’s disease, an age-related untreatable condition that has driven enormous health spending on a national scale and wrecked the finances of millions of families in the US alone. Now, with the oldest Baby Boomers just reaching age 65, Alzheimer’s disease seems destined to become a true national health crisis.
Two of the most vexing problems with this nasty disease are determining who has it and diagnosing it early enough (so scientists can understand how it progresses and someday, intervene to either cure it or halt its progression).
With current technology, the only way to accurately diagnose Alzheimer’s disease is at autopsy. Special tests of the deceased’s brain reveal the sine qua non of Alzheimer’s disease: amyloid plaques.
But last week, 2 studies appearing in JAMA provided rays of hope in this otherwise dismal state of affairs. We review them both below:
Brain Scan Detects Plaques
In the first study, scientists injected a radioactive dye known as Flobetapir F 18 into the blood of elderly volunteers, and then used PET scans to image their brains. Florbetapir F 18 had been designed by Christopher Clark and colleagues at Avid Radiopharmaceuticals to bind to amyloid proteins—which are the main constituents of amyloid plaques—and thus make them visible in vivo using the PET scan.
The PET scans correctly identified amyloid plaques in 97% of the volunteers that actually had them, as proven at autopsy. In addition, PET scans performed after the dye had been injected into young, healthy volunteers revealed no plaques.
Scientists believe the Florbetapir F 18 PET scans could be helpful as a means to exclude the diagnosis of Alzheimer’s. If no plaques are found in a patient with symptoms of dementia, physicians would be compelled to consider other causes of the symptom complex. The PET scans could also potentially be used to test drugs designed to remove amyloid from the brain.
A Blood Test for Alzheimer’s
The second study showed that blood levels of amyloid protein, as detected by a new blood test, were correlated with memory problems.
The study was directed by Kristine Yaffe at UCSF. Her group recruited 997 elderly volunteers and followed them with memory tests and amyloid blood tests for 9 years. (more…)




The Pathway Genomics kit uses saliva samples to assess one’s risk of contracting in excess of 70 diseases including lung cancer, hypertension and heart disease.
To determine the prevalence of the condition among US children aged 3 to 17 years, Michael Kogan and colleagues at the Health Resources and Services Administration and the CDC queried data from the 2007 National Survey of Children’s Health, which involved outbound calls to more than 78,000 parents.
If so, please set all that aside for a moment and take note.
The “Human Impact Report: Climate Change” was released in anticipation of a meeting of the United Nations Climate Conference to be held next winter.
The problem with all of them, according to the panel, is acetaminophen, which has long-since been linked to liver damage.
“We at Grace are gratified by today’s verdict and thank the men and women of the jury who were open to hearing the facts,” said Fred Festa, the company’s CEO in a statement obtained by
Now, a group at UNC has demonstrated using MRI scans that a specific part of the brain known as the amygdala was roughly 13% larger in autistic children than it was in normally developing kids, even after adjusting for age, gender and IQ.
“The message that we’re trying to send is, first of all, we need to respect taxpayers and how their monies are spent,” Blair told CNN. “Drug addiction is in epidemic proportions, and not only in West Virginia but throughout the United States.”




